Cancer arising from the ovaries or fallopian tubes. Most common subtype is high-grade serous carcinoma (70%). Often diagnosed at stage III/IV due to vague early symptoms and lack of effective screening. BRCA1/2 mutations increase risk significantly.

• 1Biopsy
• 2Imaging (CT, MRI, PET)
• 3Tumor markers
• 4Genetic testing
• 5Endoscopy
• 6Blood tests
• 7Screening programs

Early-stage (I-II) has 80-90% 5-year survival with surgery + chemotherapy. Advanced stage (III-IV) has 30-40% 5-year survival despite optimal cytoreduction. BRCA-mutant tumors respond better to platinum and PARP inhibitors with improved survival. Complete gross resection at primary surgery is key prognostic factor. CA-125 surveillance after treatment. Recurrent platinum-sensitive disease has 30-40% response to retreatment. Maintenance PARP inhibitors extend progression-free survival.

• Smoking cessation
• Sun protection
• Healthy diet
• Regular exercise
• Vaccination (HPV, HBV)
• Screening programs
• Limit alcohol
• Maintain healthy weight